A Randomized Phase III Study Comparing Conventional Dose Treatment using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)

Grant

Date/time Interval

  • November 18, 2013 - November 17, 2020
  • Total Award Amount

  • 40000.00
  • Direct Costs

  • 31746.00
  • Sponsor Award Id

  • Contributor

  • Donna Salzman M.D.   Investigator  
  • Racquel Innis-Shelton M.D.   Principal Investigator